Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links

Authors:
  • SCSue-Ming Chang
    Sue-Ming Chang
  • VJVicky Jain
    Vicky Jain
  • TCTai-Lin Chen
    Tai-Lin Chen
  • APAnilkumar S. Patel
    Anilkumar S. Patel
  • HPHima Bindu Pidugu
    Hima Bindu Pidugu
  • YLYi-Wen Lin
    Yi-Wen Lin
  • MWMing-Hsi Wu
    Ming-Hsi Wu
  • JHJiao-Ren Huang
    Jiao-Ren Huang
  • HWHan-Chung Wu
    Han-Chung Wu
  • TSTsann-Long Su
    Tsann-Long Su

Abstract
Hybrid molecules are composed of two pharmacophores with different biological activities. Here, we conjugated phthalazine moieties (anti-angiogenetic pharmacophore) and bis(hydroxymethyl)pyrrole moieties (DNA crosslinking agent) to form a series of bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine hybrids. These conjugates were cytotoxic to a variety of cancer cell lines by inducing DNA damage, arresting cell cycle progression at the G2/M phase, triggering apoptosis and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2) in endothelial cells. Among them, compound 29d encapsulated in a liposomal formulation (e.g., 29dL) significantly suppressed the growth of small cell lung cancer cell (H526) xenografts in mice. Based on immunohistochemical staining, the tumor xenografts in mice treated with 29dL showed time-dependent decreases in the intensity of CD31, a marker of blood vessels, whereas the intensity of γ-H2AX, a marker of DNA damage, increased. The present data revealed that the conjugation of anti-angiogenic and DNA-damaging agents can generate potential hybrid agents for cancer treatment.
Funding Information
  • Ministry of Science and Technology, Taiwan (MOST 104-2325-B-001-001, MOST 105-2325-B-001-001, MOST 107-2320-B-001-008, MOST 103-2325-B-001-018)
  • Academia Sinica (AS-102-TP-B13)

This publication has 68 references indexed in Scilit: